Background: d-Ribose is a popular dietary supplement for humans and the equine because of its crucial role in cellular bioenergetics. However, as a reducing sugar, it has been suggested that ingestion of d-ribose might promote the formation of glycated proteins in vivo with potential adverse consequences.
Objective: The aim of this study was to examine if d-Ribose would promote the formation of glycated proteins in vivo following exercise in training thoroughbred racehorses.
Methods: Two groups of horses received the supplement (30 and 50 g d-Ribose daily) for 17 weeks, during which period the horses were subjected to low-intensity exercises followed by high-intensity exercises. Blood samples were analyzed for glycated plasma proteins at baseline and following the 2 exercise regimens.
Results: This study shows that long-term ingestion of d-Ribose at 30-50 g a day does not promote the formation of glycated plasma proteins in thoroughbred racehorses. Ribose supplementation also protected the horses from cramping while enhancing muscle recovery at the same time. No adverse effects were reported.
Conclusion: Ribose supplementation is safe and does not cause glycation in vivo. This investigation also establishes safety of d-Ribose in thoroughbred racehorses, suggesting similar implications in humans as well.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/07315724.2015.1022459 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vasant Kusumakar Rasa Ameliorates Diabetic Encephalopathy by Reducing Oxidative Stress and Neuroinflammation and Improving Neurotransmitter Levels in Experimental Animals.
Cureus
December 2024
Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed to be University, Mumbai, IND.
Purpose: Diabetic encephalopathy (DE) is one of the complications of diabetes that affects the brain. In the Ayurveda system of medicine, Vasant Kusumakar Rasa (VKR) is cited as a classical herbo-mineral formulation for diabetes. However, the role of VKR in DE is still unclear.
View Article and Find Full Text PDFOxidative imbalance as a co-player in jaw functional limitations and biopsychosocial profile in patients with temporomandibular disorder-myofascial pain with referral.
Front Neurol
January 2025
Independent Laboratory of Experimental Dentistry, Medical University of Białystok, Białystok, Poland.
Introduction: Temporomandibular disorders have a multifactorial etiology including biological, biomechanical, neuromuscular, and biopsychosocial factors. Current research on temporomandibular disorders focuses on identifying clinically relevant biomarkers thus creating a new way of thinking about this dysfunction. The aim of the study was to determine the relationship between salivary/blood concentrations of oxidative/nitrosative stress biomarkers and biopsychosocial findings in patients with temporomandibular disorder-myofascial pain with referral.
View Article and Find Full Text PDFLongitudinal association between DNA methylation and type 2 diabetes: findings from the KORA F4/FF4 study.
Cardiovasc Diabetol
January 2025
Research Unit Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany.
Background: Type 2 diabetes (T2D) has been linked to changes in DNA methylation levels, which can, in turn, alter transcriptional activity. However, most studies for epigenome-wide associations between T2D and DNA methylation comes from cross-sectional design. Few large-scale investigations have explored these associations longitudinally over multiple time-points.
View Article and Find Full Text PDFEffectiveness and Safety of Vildagliptin Sustained Release in the Management of Type 2 Diabetes Mellitus: Real-World Evidence in Indian Patients [NOVELTY Study].
Drugs Real World Outcomes
January 2025
Department of Medical Affairs, Cipla Ltd., Mumbai Central, Mumbai, Maharashtra, 400008, India.
Background And Objective: Vildagliptin sustained release (XR), a formulation that provides vildagliptin 100 mg with a once-daily dose administration, is a recent introduction to manage type 2 diabetes mellitus in India. This study aimed to evaluate the effectiveness and tolerability of vildagliptin XR in patients with type 2 diabetes in real-world clinical settings.
Methods: This was an observational, prospective, multicenter, cohort study conducted in India, which included patients with type 2 diabetes uncontrolled on metformin XR monotherapy with glycated hemoglobin (HbA1c) > 7.
Early and advanced glycation end product analysis from women with PCOS on metformin.
Reprod Biol
January 2025
Biochemical Sciences Division, CSIR-National Chemical Laboratory, Pune, Maharashtra 411008, India. Electronic address:
In this cross-sectional study, we have analyzed advanced glycation end products (AGEs) in the plasma and follicular fluid of women with polycystic ovary syndrome (PCOS) taking metformin during in vitro fertilization (IVF) and control women undergoing IVF. Glucose, fructose, fructosamine, carboxymethyl lysine/ arginine (CML/R) proteins, and pentosidine were measured in the plasma and paired follicular fluid. Glycated proteins were characterized by mass spectrometry.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!